How to Conduct a First-in-Human Trial in El Salvador: A Step-by-Step Guide

Introduction

El Salvador stands at the forefront of first-in-human (FIH) clinical trials, presenting unparalleled opportunities for researchers. With the Superintendencia de Regulación Sanitaria (SRS) overseeing a streamlined approval process that can take as little as 30 days, researchers can capitalize on a dollarized economy that significantly reduces operational costs – up to 60% lower than U.S. benchmarks. Navigating local regulations can be daunting for those unfamiliar with the landscape. To fully harness these advantages, sponsors must prioritize understanding the local landscape and seek expert guidance.

Understand Regulatory Requirements for FIH Trials in El Salvador

Understanding the compliance landscape is crucial for knowing how to conduct first-in-human trial El Salvador successfully. Comprehending the compliance environment is essential, as the main regulatory body supervising research studies is the Superintendencia de Regulación Sanitaria (SRS), which took over from the previous Dirección Nacional de Medicamentos (DNM) in August 2024. Significantly, a user manual for submissions related to research studies via the SRS-CNEIS-ES platform was issued on November 17, 2025, offering revised guidance on the submission procedure. Here are the key steps to ensure compliance:

1. Familiarize Yourself with Local Regulations: Review the Salvadoran regulations governing clinical studies, including requirements set forth by the SRS and ethical guidelines from the CNEIS.
2. Prepare for Dual Review: El Salvador utilizes a parallel review process where both the SRS and CNEIS assess the study protocol simultaneously, significantly accelerating the approval process, which typically takes 30-60 days. However, this timeline can depend on submission completeness and review workload.
3. Understand Submission Requirements: Ensure that all documentation, including the research protocol, Investigator’s Brochure, ethics approvals, safety data, and site documentation, are prepared in Spanish and meet the SRS’s standards.
4. Adherence to ICH-GCP: Follow the International Conference on Harmonisation – Good Clinical Practice (ICH-GCP) guidelines, which are compulsory for all trials conducted in El Salvador. This compliance is essential for FDA acceptance of clinical data.
5. Engage Local Experts: Partnering with local CROs or regulatory consultants experienced in navigating the Salvadoran regulatory environment can facilitate the approval process and enhance compliance.

Navigating the Salvadoran regulatory landscape can be daunting for first-time researchers. The SRS-CNEIS-ES platform streamlines the submission process. It offers step-by-step guidance, standardized document templates, and real-time status tracking. These features are vital for maintaining efficient workflows and avoiding delays. With around 60% cost reductions compared to similar US programs, El Salvador emerges as an appealing location for how to conduct first-in-human trial El Salvador, thanks to its dollarized economy that reduces exchange rate risks and lower operational expenses. Moreover, bioaccess® has effectively assisted innovators such as Axoft and Newrotex in utilizing this compliance framework to understand how to conduct first-in-human trial El Salvador, showcasing the efficiency of the LATAM pathway in accelerating research. By leveraging local expertise and adhering to regulatory standards, researchers can unlock the potential of El Salvador as a prime location for innovative clinical trials.

Prepare Documentation and Submission for Clinical Trials

Navigating the regulatory landscape for how to conduct first-in-human trial El Salvador requires meticulous documentation preparation. To ensure a smooth submission process, follow these essential steps:

1. Compile Required Documents: Gather all essential documents, including:

   • Clinical trial protocol
   • Investigator’s Brochure
   • Informed consent forms
   • Ethics committee approval letters
   • Product information and safety data
   • Preclinical documentation, including biocompatibility testing, material characterization, software validation, and animal studies as required for First-in-Human trials.

2. Translate Documents: All documents must be translated into Spanish, as this is a requirement for presentation to the Superintendencia de Regulación Sanitaria (SRS) and the Comisión Nacional de Ética en Investigación (CNEIS). Translation delays can significantly hinder your trial’s start, so it’s crucial to plan ahead.

3. Utilize the SRS-CNEIS-ES Platform: Submit your application through the SRS-CNEIS-ES platform, which enables simultaneous processing to both the SRS and CNEIS. This platform offers a structured workflow for entries, streamlining the review process and enabling real-time tracking of your entry status.

4. Monitor Status Updates: Make it a habit to check the platform for updates on your entry. Engage proactively with regulatory authorities to address any questions or concerns that may arise during the review process, ensuring transparency and efficiency. Be ready for potential bureaucratic delays that could impact your overall timeline.

5. Prepare for Potential Revisions: Be ready to make adjustments to your entry based on feedback from the SRS or CNEIS. Without timely responses, your approval process could stall, leading to unnecessary delays. Adhering to ICH-GCP standards is essential to guarantee the quality and safety of your research studies.

By following these guidelines on how to conduct first-in-human trial El Salvador, you can enhance the effectiveness of your documentation preparation and filing, ultimately enabling a quicker route to approval. By leveraging bioaccess®’s expertise, you can not only streamline your submission but also enhance the likelihood of swift approval.

Execute the Trial: Site Selection and Patient Recruitment Strategies

Navigating the complexities of how to conduct first-in-human trial El Salvador requires meticulous planning and strategic foresight. Here’s a structured approach to these essential components:

1. Identify Suitable Sites: Evaluate potential clinical trial sites based on:

   • Previous experience with FIH trials, ensuring familiarity with regulatory requirements and protocols.
   • Availability of qualified investigators who can lead the study effectively.
   • Access to the target patient population, which is crucial for meeting enrollment goals.
   • Infrastructure and resources to support the study, including medical equipment and facilities compliant with ICH-GCP standards.

2. Conduct Feasibility Assessments: Perform thorough feasibility studies at selected sites to assess their capability to meet enrollment targets and adhere to protocol requirements. This encompasses evaluating the site’s historical performance in similar studies and understanding local regulatory environments, such as those overseen by INVIMA.

3. Develop a Patient Recruitment Plan: Create a comprehensive recruitment strategy that includes:

   • Engaging local healthcare providers to refer eligible patients, leveraging their networks to enhance outreach.
   • Utilizing digital marketing and social media to reach potential participants, which has proven effective in increasing visibility and interest.
   • Hosting informational sessions to educate the community about the study, addressing any concerns and building trust.

4. Leverage Community Engagement: Build relationships with local patient advocacy groups and community organizations to enhance trust and encourage participation. Building these relationships is crucial for connecting with underrepresented populations and ensuring diverse enrollment.

5. Monitor Recruitment Progress: Track enrollment metrics closely and adjust recruitment strategies as needed to ensure that targets are met within the study timeline. Regular updates to stakeholders about recruitment progress can maintain engagement and facilitate timely decision-making.

Implementing these strategies allows sponsors to improve site selection and patient recruitment. This enhancement ultimately leads to understanding how to conduct first-in-human trial El Salvador successfully. The region’s regulatory pathways allow for approvals in just 4-8 weeks, significantly faster than the 6+ months typical in the US/EU. Moreover, with cost efficiencies of about 30% lower per-patient expenses compared to US benchmarks, bioaccess® offers a strategic edge for early-stage clinical evaluations, making it an optimal selection for MedTech, Biopharma, and Radiopharma firms looking to expedite their clinical development and market entry.

Monitor Compliance and Ensure Quality Throughout the Trial

To uphold the integrity of your first-in-human study in El Salvador, it is essential to understand how to conduct first-in-human trial El Salvador with robust monitoring and quality assurance practices. Follow these steps:

1. Establish a Monitoring Plan: Develop a comprehensive monitoring plan that outlines the frequency and methods of monitoring activities, including:

   • Site visits
   • Remote monitoring techniques
   • Data verification processes

2. Conduct Regular Site Visits: Schedule consistent visits to research locations to evaluate adherence to the protocol, ICH-GCP guidelines, and local regulations. These visits also offer a chance to train and support site staff, making sure they’re well-equipped to meet study requirements.

3. Implement Risk-Based Monitoring: Utilize a risk-based monitoring approach to focus resources on sites and activities that present the highest risk to participant safety and data integrity. This method facilitates effective distribution of monitoring efforts, improving overall study quality.

4. Ensure Timely Reporting of Adverse Events: Establish clear procedures for reporting adverse events and ensure that all site staff are trained on these protocols. Prompt reporting is crucial for maintaining participant safety and regulatory compliance, particularly in the context of El Salvador’s streamlined regulatory processes.

5. Review Data Continuously: Make it a point to regularly review the collected data to ensure accuracy and completeness. Address any discrepancies promptly to maintain the quality of the study. Continuous data oversight is vital, especially given that every data query incurs an average cost of $150, emphasizing the need for efficient data management practices.

Did you know that El Salvador’s research environment has expanded by about 160% from 2020 to 2023? The country’s dollarized economy and rapid startup times of 30-60 days further enhance its appeal, providing significant cost savings of around 60% compared to U.S. programs. By following these monitoring practices, you can ensure adherence to regulations. This approach maintains the integrity of your clinical studies in this promising region. Additionally, with bioaccess®, you can expect to learn how to conduct first-in-human trial El Salvador within 6-8 weeks and deliver FDA-bridgeable data approximately 40% faster than traditional US/EU pathways. With these practices in place, you position your studies for success in a rapidly evolving research landscape.

Conclusion

El Salvador presents a unique opportunity for first-in-human trials, combining regulatory efficiency with cost-effectiveness. Researchers can initiate trials in El Salvador within 6-8 weeks by utilizing the streamlined processes of the Superintendencia de Regulación Sanitaria (SRS) and the Comisión Nacional de Ética en Investigación (CNEIS). This is significantly faster than traditional timelines in the US or EU. With the potential for cost savings of around 30% per patient, El Salvador becomes an appealing choice for MedTech, Biopharma, and Radiopharma companies.

What challenges do you face in understanding local regulatory requirements? Key insights from this guide emphasize the importance of:

• Thorough documentation
• Effective site selection
• Patient recruitment strategies

Engaging local experts and utilizing the SRS-CNEIS-ES platform can further streamline the submission process, ensuring compliance with ICH-GCP standards and enhancing the likelihood of swift approvals. Additionally, robust monitoring and quality assurance practices are essential to maintain the integrity of clinical studies throughout their duration.

The advantages of conducting first-in-human trials in El Salvador are compelling. By embracing the region’s regulatory efficiencies and cost benefits, innovators can accelerate their clinical development timelines and bring groundbreaking therapies to market more rapidly. For those ready to embrace innovation, El Salvador stands as a beacon of opportunity in the evolving landscape of clinical research.

Frequently Asked Questions

What is the main regulatory body overseeing first-in-human trials in El Salvador?

The main regulatory body is the Superintendencia de Regulación Sanitaria (SRS), which took over from the Dirección Nacional de Medicamentos (DNM) in August 2024.

What is the significance of the SRS-CNEIS-ES platform?

The SRS-CNEIS-ES platform streamlines the submission process for research studies, providing step-by-step guidance, standardized document templates, and real-time status tracking.

What are the key steps to ensure compliance for FIH trials in El Salvador?

Key steps include familiarizing yourself with local regulations, preparing for dual review by the SRS and CNEIS, understanding submission requirements, adhering to ICH-GCP guidelines, and engaging local experts.

How does the dual review process work in El Salvador?

El Salvador employs a parallel review process where both the SRS and CNEIS assess the study protocol simultaneously, which can significantly accelerate the approval process, typically taking 30-60 days.

What are the submission requirements for conducting trials in El Salvador?

All documentation, including the research protocol, Investigator’s Brochure, ethics approvals, safety data, and site documentation, must be prepared in Spanish and meet the SRS’s standards.

Why is adherence to ICH-GCP important for trials in El Salvador?

Adherence to ICH-GCP guidelines is compulsory for all trials in El Salvador and is essential for the FDA acceptance of clinical data.

How can local expertise assist in the regulatory process?

Partnering with local CROs or regulatory consultants experienced in the Salvadoran regulatory environment can facilitate the approval process and enhance compliance.

What are the cost advantages of conducting trials in El Salvador compared to the US?

Conducting trials in El Salvador can result in around 60% cost reductions compared to similar US programs, with operational expenses being lower due to the dollarized economy.

Can you provide examples of companies that have successfully navigated the regulatory framework in El Salvador?

bioaccess® has effectively assisted innovators such as Axoft and Newrotex in utilizing the compliance framework for conducting first-in-human trials in El Salvador.

List of Sources

1. Understand Regulatory Requirements for FIH Trials in El Salvador
   • User Guide for Clinical Trial Submissions on the SRS–CNEIS-ES Platform: El Salvador 2025 (https://regdesk.co/blog/user-guide-for-clinical-trial-submissions-on-the-srs-cneis-es-platform-el-salvador-2025)
   • Clinical trials in el salvador | FIH device studies | bioaccess® (https://bioaccessla.com/clinical-trials-el-salvador)
   • El Salvador’s Ministry of Health Proposes Clinical Trials Law for Better Regulation. (https://elsalvadorinenglish.com/2025/02/05/el-salvadors-ministry-of-health-proposes-clinical-trials-law-for-better-regulation)
2. Prepare Documentation and Submission for Clinical Trials
   • User Guide for Clinical Trial Submissions on the SRS–CNEIS-ES Platform: El Salvador 2025 (https://regdesk.co/blog/user-guide-for-clinical-trial-submissions-on-the-srs-cneis-es-platform-el-salvador-2025)
   • Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC9116999)
3. Execute the Trial: Site Selection and Patient Recruitment Strategies
   • Clinical Trials Patient Recruitment in Latin America | H Clinical (https://hclinical.com/patient-recruitment)
   • Online Patient Recruitment in Clinical Trials: Systematic Review and Meta-Analysis – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC7673977)
   • Rate of Patient Recruitment to International Multicenter Clinical Studies in Eastern Europe Countries | Applied Clinical Trials Online (https://appliedclinicaltrialsonline.com/view/rate-of-patient-recruitment-to-international-multicenter-clinical-studies-in-eastern-europe-countries)
   • Evaluation of factors associated with recruitment rates in early phase clinical trials based on the European Clinical Trials Register data – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC10719455)
4. Monitor Compliance and Ensure Quality Throughout the Trial
   • Clinical trials in el salvador | FIH device studies | bioaccess® (https://bioaccessla.com/clinical-trials-el-salvador)
   • Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC11029458)
   • Importance of Quality Assurance in Clinical Trials | Within3 (https://within3.com/blog/importance-of-quality-assurance-in-clinical-trials)
   • Clinical trial monitoring | MED Institute (https://medinstitute.com/blog/clinical-trial-monitoring)
   • A new trial monitoring plan (TMP) template for clinical trials: output from a Delphi process – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC11549859)